Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

The Anticancer Mechanism of the Ribonucleotide Reductase Inhibiting Drug COH29 Involves Suppression of DNA Repair


ABSTRACT: Mechanism of Action Study for COH29 Compare COH29 treatment in DNA-repair deficient cell line with truncated BRCA1 (HCC1937) versus phenotypically normal cell line with exogenous WT BRCA1 expression (HCC1937+BRCA1)

ORGANISM(S): Homo sapiens

SUBMITTER: Charles Warden 

PROVIDER: E-GEOD-55004 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine because of its critical role in DNA replication and repair. Herein we report that BRCA-1-defective human breast  ...[more]

Similar Datasets

2015-05-08 | GSE55004 | GEO
2011-12-24 | E-GEOD-30821 | biostudies-arrayexpress
2017-02-14 | E-MTAB-5468 | biostudies-arrayexpress
2017-02-14 | E-MTAB-5465 | biostudies-arrayexpress
2011-12-24 | GSE30821 | GEO
2011-12-24 | GSE30763 | GEO
2011-12-24 | E-GEOD-30763 | biostudies-arrayexpress
2013-06-08 | E-GEOD-42307 | biostudies-arrayexpress
2015-02-18 | E-GEOD-58642 | biostudies-arrayexpress
2016-07-03 | E-GEOD-47403 | biostudies-arrayexpress